Articles related to PRECISION MEDICINE

Tempus AI, leveraging one of the world’s largest clinical and molecular oncology data libraries, files for an IPO, aiming to raise substantial funds to support its mission of advancing AI-powered precision medicine.

In a recent phase 3 trial, asciminib has shown superior efficacy and safety in newly diagnosed chronic myeloid leukemia patients, achieving a higher major molecular response rate at week 48 compared to traditional tyrosine kinase inhibitors.

Manifest Technologies is spearheading the use of AI in developing targeted treatments for CNS disorders, aiming to refine patient selection in clinical trials and enhance therapeutic outcomes.

Wearable digital health technologies are setting a new standard in patient care, offering insights into daily physiological and behavioral patterns that were previously inaccessible, enabling a more nuanced approach to disease management and patient engagement.

As physicians, understanding the new biomarker legislation is crucial—it not only shapes insurance coverage but also influences clinical decision-making and patient access to precision medicine, potentially leading to more cost-effective and targeted care.

Explore the transformative potential of antibody-drug conjugates (ADCs) in cancer therapy, offering targeted treatments with reduced side effects. Recent approvals and ongoing trials signify a significant shift towards precision medicine in oncology.